Stacey Chang-Douglass
Head of Health Economics and Director in Consulting
Stacey is Head of Health Economics and Director in Consulting at Clarivate.
Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.
Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.
Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.
Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.
Latest news
Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI
New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions London, U.K. November 24, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider…
Clarivate RiskMark Wins 2025 LegalTech Breakthrough Award For “LegalTech Predictive AI Solution of the Year”
Annual awards program recognizes companies and products driving innovation in the global legal technology industry AI-powered RiskMark delivers near-instant, data-backed insights London, U.K. November 13, 2025. Clarivate Plc (NYSE:CLVT), a…
